Posted by Michael Wonder on 30 Dec 2025
FDA accepts for review Inovio's BLA for INO-3107 for the treatment of adults with recurrent respiratory papillomatosis
29 December 2025 - Inovio today announced that the US FDA accepted the company's niologics license application for INO-3107 for review as a potential treatment for adults with recurrent respiratory papillomatosis.
The review classification designated by FDA is standard. The FDA assigned INO-3107 a PDUFA review goal date of 30 October 2026.
